Alantra advises Sangamo Therapeutics on the acquisition of TxCell

December 18, 2018

Alantra, a global investment banking and asset management company focused on the mid-market segment, has acted as sole M&A advisor to Sangamo Therapeutics, a leading development company of technologies for gene-based therapies, on the acquisition of TxCell, a French listed biotech specialized in CAR-Tregs.

The transaction was structured in two parts: an off-market block acquisition from historical shareholders (founder, management, Belsize Asset Management, Auriga, bpifrance and Yorkville) in July 2018, followed by a simplified mandatory tender offer to acquire the shares not yet owned by Sangamo Therapeutics.

Following the tender offer, Sangamo Therapeutics reached the 95% threshold and therefore squeezed-out minority shareholders and delisted the company.

Alantra advised Sangamo Therapeutics in the competitive auction process and acted as presenting and guaranteeing bank for the public tender offer.

The deal represents the sixth listed transaction advised by Alantra in the last two years in France, proving Alantra’s expertise in stock exchange transactions and a great achievement in the development of Alantra in France.

By Yago Sánchez December 18, 2018 Corporate News, Press Releases

Related Posts